Medtronic's Resolute Integrity DES Compared to Bioabsorbable DES in OCT-ORION

May 19, 2016—Results from the OCT-ORION trial demonstrated that the durable-polymer Resolute Integrity drug-eluting stent (DES, Medtronic plc) performed significantly better than the bioabsorbable polymer BioMatrix Flex and NeoFlex DES (Biosensors International Group, Ltd.). The OCT-ORION data were presented at the EuroPCR 2016 conference held May 17–20 in Paris, France. The principal investigator of OCT-ORION is Prof. Stephen Lee, MD, from the University of Hong Kong in China.

OCT-ORION, which was composed of 60 patients, measured vessel healing by strut coverage postimplantation at various intervals with a primary endpoint at 9 months. At each interval, the Resolute Integrity performed significantly better than the BioMatrix Flex and NeoFlex.

The investigators reported that at 2 months, 92.2% of patients demonstrated improved early rapid healing with the Resolute Integrity DES versus 86.5% for the BioMatrix DES (P = .06). At 3 months, the Resolute Integrity DES showed a statistically significant improvement in early healing versus the BioMatrix DES (95.4% vs 86.6%; P = .0035). At 9 months, the Resolute Integrity DES continued to show better strut coverage that was statistically significant (99.7% vs 99.6%; P = .0009). More than half of the patients in OCT-ORION were diabetic (n = 33), and results were also superior for the Resolute Integrity in rapid healing outcomes.

Bioabsorbable polymer DES devices continue to show no clinical benefit over durable polymer DES such as Resolute Integrity, concluded the investigators.